​JLL Partners and Royal DSM complete US$1.98 billion acquisition of Patheon Inc. 

Date Closed: 3/11/2014

Value:  US $1.98 billion

On March 11, 2014, Patheon Inc. (Patheon) completed a court-approved statutory plan of arrangement (the Arrangement) under the Canada Business Corporations Act under which Patheon was acquired for US$9.32 per share in cash resulting in a total enterprise value for Patheon of approximately US$1.98 billion.

In connection with the Arrangement, JLL Partners (JLL), the middle-market private equity firm, and Royal DSM (DSM), the global Life Sciences and Materials Sciences company combined DSM Pharmaceutical Products and Patheon into a new privately held company, named DPx Holdings B.V. (DPx).

BLG represented JLL and its affiliates in Canada with a team led by Paul Mingay that included Jason Saltzman and Andrew Bunston (M&A/securities), Steve Suarez (tax), and Colin MacDonald (competition/foreign investment).